Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

538.000
+5.0000.94%
Volume:561.82K
Turnover:301.87M
Market Cap:128.58B
PE:-278.28
High:545.000
Open:541.500
Low:527.500
Close:533.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.80
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.933
ROE:2.92%
ROA:0.03%
PB:20.65
PE(LYR):-278.28
PS:52.83

Loading ...

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 30

Kelun-Biotech (SKB BIO): NMPA Accepts Sixth Indication Filing for TROP2 ADC sac-TMT as First-Line Therapy in PD-L1-Low TNBC

Bulletin Express
·
Jul 30

Kelun-Biotech Says China Regulator Accepts sac-TMT Filing for First-line Metastatic TNBC Use

Reuters
·
Jul 30

Sichuan Kelun-Biotech Biopharmaceutical Co - Nmpa Accepts New Indication Application for Sac-TMT in First-Line Tnbc

THOMSON REUTERS
·
Jul 30

Movement Alert|SKB BIO Declines 3.01% in Regular Trading, Trading at 482.6 HKD

Market Focus
·
Jul 30

MerckRapidly Advances ADC+IO 2.0 Strategy with SKB BIO's TROP2 ADC Joint PD-1/VEGF Bispecific Antibody Phase II Trial

Deep News
·
Jul 29

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA IND Approval for Skb565

Reuters
·
Jul 27

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-Payload ADC Skb565

THOMSON REUTERS
·
Jul 27

SKB BIO Receives NMPA Approval for Clinical Trial of Novel Dual-Load ADC Drug

Stock News
·
Jul 27

Kelun-Biotech Wins China IND Clearance for Skb565 in Advanced Solid Tumors

Reuters
·
Jul 27

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives Nmpa Ind Approval for Skb565 for Advanced Solid Tumors

THOMSON REUTERS
·
Jul 27

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.62% at Open, Investment Banks Raise Target Prices Amid Institutional Accumulation Wave

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.08% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Institutional Buying Wave

Market Focus
·
Jul 21

JPMorgan Raises Price Target for SKB BIO to HK$648, Maintains Overweight Rating

Deep News
·
Jul 20

Movement Alert|Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound

Market Focus
·
Jul 20

Movement Alert|Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness

Market Focus
·
Jul 17

HBM Holdings's Asthma Drug Candidate Secures China's Approval

MT Newswires Live
·
Jul 16

Goldman Sachs Reiterates Buy Rating on Kelun-Bota Biopharma, Raises Target Price to HK$582.95

Deep News
·
Jul 16

Movement Alert|Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally

Market Focus
·
Jul 16